Camptothecin/Fleximer conjugate

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameCamptothecin/Fleximer conjugate
Drug Alias NameXMT-1001MER-1001
ClassificationSmall molecules
Mechanisms of ActionDNA topoisomerase I inhibitors
TargetsDNA topoisomerase I
Therapy Area/IndicationsSmall Cell Lung CarcinomaCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsYes Camptothecin
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMersana Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMersana Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsSmall Cell Lung CarcinomaCarcinoma, Non-Small-Cell Lung

Other Information

ATC CodeN/A
Related LinksDrugBank